SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.230
-0.120 (-8.87%)
At close: Apr 1, 2025, 4:00 PM
1.279
+0.049 (3.99%)
After-hours: Apr 1, 2025, 7:58 PM EDT

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
11356330340-
Upgrade
Market Cap Growth
-44.79%-44.79%113.36%-91.25%--
Upgrade
Enterprise Value
-496627336-
Upgrade
Last Close Price
1.363.796.885.9078.10-
Upgrade
PS Ratio
9.5326.4828.331.245.58-
Upgrade
PB Ratio
0.491.351.110.968.81-
Upgrade
P/TBV Ratio
1.351.351.110.968.81-
Upgrade
P/OCF Ratio
---170.89-
Upgrade
EV/Sales Ratio
6.916.9129.321.145.51-
Upgrade
Debt / Equity Ratio
0.180.180.100.190.220.21
Upgrade
Debt / EBITDA Ratio
-----0.38
Upgrade
Asset Turnover
0.020.020.030.360.881.48
Upgrade
Quick Ratio
2.612.615.231.371.563.00
Upgrade
Current Ratio
2.982.985.451.471.903.12
Upgrade
Return on Equity (ROE)
-81.92%-81.92%-95.51%-53.85%-44.21%86.15%
Upgrade
Return on Assets (ROA)
-41.86%-41.86%-35.30%-27.37%-12.16%34.47%
Upgrade
Return on Capital (ROIC)
-57.16%-57.16%-47.50%-43.00%-17.77%41.14%
Upgrade
Return on Capital Employed (ROCE)
-----45.20%
Upgrade
Earnings Yield
-271.72%-97.39%-66.52%-63.04%-5.05%-
Upgrade
FCF Yield
-275.89%-98.89%-39.91%-86.20%-2.64%-
Upgrade
Buyback Yield / Dilution
-67.74%-67.74%-26.86%-59.20%-1.21%23.30%
Upgrade
Updated Nov 6, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q